Magnus Lindskog
Overview
Explore the profile of Magnus Lindskog including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
408
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Branstrom R, Zedenius J, Shabo I, Lindskog M, Juhlin C
Case Rep Oncol
. 2024 Oct;
17(1):1124-1130.
PMID: 39474531
Introduction: Clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer in adults, presents significant challenges owing to its resistance to conventional therapies. Standard treatment primarily revolves...
2.
Lindskog M, Mogensen H, Tavelin B, Eknert J, Lundstrom S, Strang P
BMC Palliat Care
. 2024 Jul;
23(1):178.
PMID: 39026303
Background: Parenteral fluid (PF) therapy of patients in end-of-life (EOL) is controversial. The purpose of this study was to assess associations between PF, quality of the EOL care process and...
3.
Marvaso G, Jereczek-Fossa B, Zaffaroni M, Vincini M, Corrao G, Andratschke N, et al.
Lancet Oncol
. 2024 May;
25(5):e193-e204.
PMID: 38697165
The purpose of this European Society for Radiotherapy and Oncology (ESTRO) project, endorsed by the European Association of Urology, is to explore expert opinion on the management of patients with...
4.
Selvin T, Berglund M, Lenhammar L, Lindskog M, Jarvius M, Larsson R, et al.
BMC Pharmacol Toxicol
. 2024 Mar;
25(1):25.
PMID: 38444002
Background: It has become evident in the field of oncology that the outcome of medical treatment is influenced by the combined effect exerted on both cancer- and immune cells. Therefore,...
5.
Werlenius K, Kinhult S, Solheim T, Magelssen H, Lofgren D, Mudaisi M, et al.
JAMA Netw Open
. 2023 Mar;
6(3):e234149.
PMID: 37000452
Importance: Disulfiram has demonstrated broad antitumoral effect in several preclinical studies. One of the proposed indications is for the treatment of glioblastoma. Objective: To evaluate the efficacy and safety of...
6.
Tsakonas G, Koulouris A, Kazmierczak D, Botling J, Ortiz-Villalon C, Nord H, et al.
Int J Mol Sci
. 2023 Jan;
24(1).
PMID: 36613642
Distant spreading of tumor cells to the central nervous system in non-small cell lung cancer (NSCLC) occurs frequently and poses major clinical issues due to limited treatment options. RNAs displaying...
7.
Karlsson Rosenblad A, Sundqvist P, Harmenberg U, Hellstrom M, Hofmann F, Kjellman A, et al.
Scand J Urol
. 2022 Aug;
56(5-6):383-390.
PMID: 35983600
Objective: To examine the association between surgical waiting times (SWTs) and all-cause mortality (ACM) in non-metastatic patients with RCC, in relation to tumour stage. Patients And Methods: This nation-wide population-based...
8.
Lindskog M, Schultz T, Strang P
BMC Palliat Care
. 2022 Jul;
21(1):133.
PMID: 35869460
Background: Patients with progressive primary brain tumors commonly develop a spectrum of physical as well as cognitive symptoms. This places a large burden on family members and the condition's complexity...
9.
Lindskog M, Laurell A, Kjellman A, Melichar B, Rey P, Zielinski H, et al.
Eur Urol Open Sci
. 2022 May;
40:38-45.
PMID: 35638086
Background: The prognosis of patients with synchronous metastatic renal cell carcinoma (mRCC) is poor. Whereas single-agent tyrosine kinase inhibition (TKI) is clearly insufficient, the effects can be enhanced by combinations...
10.
Almdalal T, Sundqvist P, Harmenberg U, Hellstrom M, Lindskog M, Lindblad P, et al.
Eur Urol Open Sci
. 2022 May;
39:22-28.
PMID: 35528783
Background: T1a renal cell carcinoma (RCC) is typically considered a curable disease, irrespective of the choice of local treatment modality. Objective: To identify factors associated with the risk of local...